RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/25092144http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25092144http://www.w3.org/2000/01/rdf-schema#comment"Almost 30% of all acute myeloid leukemias (AML) are associated with an internal tandem duplication (ITD) in the juxtamembrane domain of FMS-like tyrosine kinase 3 receptor (FLT3). Patients with FLT3-ITD mutations tend to have a poor prognosis. MicroRNAs (miRNAs) have a pivotal role in myeloid differentiation and leukemia. MiRNA-155 (MiR-155) was found to be upregulated in FLT3-ITD-associated AMLs. In this study, we discovered that FLT3-ITD signaling induces the oncogenic miR-155. We show in vitro and in vivo that miR-155 expression is regulated by FLT3-ITD downstream targets nuclear factor-κB (p65) and signal transducer and activator of transcription 5 (STAT5). Further, we demonstrate that miR-155 targets the myeloid transcription factor PU.1. Knockdown of miR-155 or overexpression of PU.1 blocks proliferation and induces apoptosis of FLT3-ITD-associated leukemic cells. Our data demonstrate a novel network in which FLT3-ITD signaling induces oncogenic miR-155 by p65 and STAT5 in AML, thereby targeting transcription factor PU.1."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.org/dc/terms/identifier"doi:10.1038/leu.2014.231"xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Duyster J."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Muller-Tidow C."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Madan V."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Tenen D.G."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Behre G."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Gerloff D."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Wurm A.A."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Niederwieser D."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Grundler R."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Brauer-Hartmann D."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Hartmann J.U."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/author"Katzerke C."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/name"Leukemia"xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/pages"535-547"xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/title"NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia."xsd:string
http://purl.uniprot.org/citations/25092144http://purl.uniprot.org/core/volume"29"xsd:string
http://purl.uniprot.org/citations/25092144http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/25092144
http://purl.uniprot.org/citations/25092144http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/25092144
http://purl.uniprot.org/uniprot/#_A0A087X0W8-mappedCitation-25092144http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25092144
http://purl.uniprot.org/uniprot/#_A8K6I5-mappedCitation-25092144http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25092144
http://purl.uniprot.org/uniprot/#_A0A384N5W4-mappedCitation-25092144http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25092144